Acute Myeloid Leukemia (AML)

Dr. Ivana Gojo is a Hematologist/Oncologist in Baltimore. Her clinical focus is on diagnosis and management of patients with acute leukemias (AML, ALL) and other myeloid malignancies (MDS, MPNs, CML), with emphasis on the development of novel therapeutic approaches for these diseases. She is nationally and internationally recognized expert in clinical translation of novel therapeutics for acute leukemias and principal investigator on multiple multi-center investigator-initiated studies. Dr. Gojo joined the Johns Hopkins faculty in 2012 as the Co-Director of Leukemia Drug Development Program

Catherine Chittick, RN, BSN is an oncology nurse at the Massachusetts General Hospital (MGH), where she has been employed for five years since the start of her career. After graduating from Sacred Heart University (Fairfield, CT) School of Nursing in 2015, Catherine joined the nursing profession as a registered nurse at the MGH as part of the eCare Nursing Residency program for new graduates. She has both outpatient and inpatient experience, working first in an outpatient infusion nurse caring for leukemia and bone marrow transplant patients before moving inpatient to care for patients with

Jenna Moran, MSN, FNP-BC, is an oncology nurse practitioner with the Leukemia department at the Massachusetts General Hospital Cancer Center in Boston, MA. She has experience in both the ambulatory and inpatient care settings. Her current areas of clinical focus include acute myeloid leukemia, acute lymphocytic leukemia, chronic myeloid leukemia and myelodysplastic syndrome. She has worked as clinical faculty at Simmons College as an instructor for medical surgical nursing. Additionally, she has worked as a global health nurse educator providing bone marrow transplant education and training to

Aura Ramos, RN, BSN, is a leukemia research nurse at the Massachusetts General Hospital Cancer Center in Boston for the past 6 years. Aura has over 16 years of nursing experience caring for oncology patients in the ambulatory and inpatient setting. Prior to becoming a research nurse, she worked as a staff nurse on the leukemia and bone marrow transplant unit. She had the opportunity to travel to Dhaka, Bangladesh and educate nurses on caring for bone marrow transplant and leukemia patients. As a research nurse, she continues to educate staff on the administration of new research oral and

Dr. Zeidner's research interests include discovering innovative methods to improve outcomes, drug discovery and development, and designing clinical trials in acute myeloid leukemia (AML) myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs). He leads the Leukemia Clinical Trials Research Protocol Office Disease (POD) Group where we have a multitude of cutting-edge clinical trials for acute leukemia, MDS, and MPNs. Dr. Zeidner's the Principal Investigator of industry-sponsored, investigator-initiated, and academic collaborative clinical trials evaluating novel agents in MDS

Katherine Tarlock, M.D., is a board certified physician at Seattle Children’s Hospital and a UW assistant professor of pediatrics. Dr. Tarlock believes the privilege of caring for patients and families during challenging medical diagnoses is what drew her to this field and continues to be the best part of her job. She is dedicated to advancing our understanding of leukemia and being able to offer every child and family the best care. Dr. Tarlock earned her M.D. at Chicago Medical School. She is board certified in both Pediatrics and Pediatric Hematology/Oncology.